Skip to main content

Bristol-Myers Value Stock - Dividend - Research Selection

Bristol-myers

ISIN: US1101221083 , WKN: 850501

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for the treatment of anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. The company\'s products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a strategic collaboration agreement with Nektar Therapeutics, Illumina, Inc., and Janssen Pharmaceuticals, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

2023-03-16
In the latest trading session, Bristol Myers Squibb (BMY) closed at $67.10, marking a -0.56% move from the previous day.

The Fall Of SVB: What It Means For Healthcare Startups

2023-03-16
How SVB's collapse is impacting healthcare startups. Pfizer to buy Seagen for $43B. What it means for the sector.

Got $5,000? These 2 High-Yielding Dividend Stocks Are Near Their 52-Week Lows

2023-03-16
A positive consequence of a bear market is that there are plenty of good opportunities for investors to buy stocks at reduced prices. Two stocks that stand out in particular to me right now include Bristol Myers Squibb (NYSE: BMY) and Verizon Communications (NYSE: VZ). Bristol Myers Squibb is a type of investment that I could see Warren Buffett owning in his portfolio.

UK earnings, trading statements calendar - next 7 days

2023-03-16
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Interesting BMY Put And Call Options For May 19th

2023-03-16
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Evotec Shares Rise After Drug Progress Earns Payment From Bristol Myers Squibb

2023-03-16
By David Sachs Shares in Evotec SE gained in early trading Thursday on news that progress on a new set of oncology drugs triggered a payment from its...

Bristol Myers Squibb Co. stock outperforms market on strong trading day

2023-03-15
Shares of Bristol Myers Squibb Co. advanced 1.52% to $67.48 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the...

Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments

2023-03-15
PRINCETON, N.J., March 15, 2023--Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments

Bloomsbury Publishing expects revenue, profit ahead of expectations

2023-03-15
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

SMALL-CAP WINNERS & LOSERS: Bloomsbury tops forecast; Hyve backs offer

2023-03-15
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.